TScan Therapeutics (NASDAQ:TCRX) Cut to "Strong Sell" at Wall Street Zen

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a note issued to investors on Saturday.

Several other equities research analysts also recently issued reports on the company. Wedbush boosted their price objective on TScan Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a report on Thursday, March 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of TScan Therapeutics in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $6.00.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $1.26 on Friday. TScan Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $2.57. The company has a debt-to-equity ratio of 0.34, a quick ratio of 8.41 and a current ratio of 6.65. The company has a 50 day moving average price of $1.11 and a 200 day moving average price of $1.15. The stock has a market capitalization of $71.69 million, a P/E ratio of -1.31 and a beta of 1.06.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.22). The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $2.50 million. TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%. Equities research analysts forecast that TScan Therapeutics will post -1.05 EPS for the current year.

Institutional Investors Weigh In On TScan Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of TCRX. Panagora Asset Management Inc. acquired a new position in TScan Therapeutics during the 4th quarter worth $25,000. HRT Financial LP acquired a new position in TScan Therapeutics during the 4th quarter worth $26,000. Boothbay Fund Management LLC grew its stake in TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company's stock worth $35,000 after purchasing an additional 8,121 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in TScan Therapeutics during the 1st quarter worth $63,000. Finally, Marshall Wace LLP acquired a new position in TScan Therapeutics during the 2nd quarter worth $78,000. Hedge funds and other institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan's approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company's pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.